Trial · NCT02047045
Results by group110
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 110
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 3-8 | Electro-acupuncture | 36.2 | percentage of participants | ||
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 3-8 | Prucalopride | 37.8 | percentage of participants | ||
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 1-2, 11-12, 15-16, 19-20, 31-32. | Electro-acupuncture | weeks 1-2 | 27.1 | percentage of participants | |
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 1-2, 11-12, 15-16, 19-20, 31-32. | Prucalopride | weeks 1-2 | 33.8 | percentage of participants | |
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 1-2, 11-12, 15-16, 19-20, 31-32. | Electro-acupuncture | weeks 11-12 | 38.3 | percentage of participants | |
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 1-2, 11-12, 15-16, 19-20, 31-32. | Prucalopride | weeks 11-12 | 43.2 | percentage of participants | |
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 1-2, 11-12, 15-16, 19-20, 31-32. | Electro-acupuncture | weeks 15-16 | 38.0 | percentage of participants | |
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 1-2, 11-12, 15-16, 19-20, 31-32. | Prucalopride | weeks 15-16 | 41.0 | percentage of participants | |
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 1-2, 11-12, 15-16, 19-20, 31-32. | Electro-acupuncture | weeks 19-20 | 35.7 | percentage of participants | |
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 1-2, 11-12, 15-16, 19-20, 31-32. | Prucalopride | weeks 19-20 | 42.1 | percentage of participants | |
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 1-2, 11-12, 15-16, 19-20, 31-32. | Electro-acupuncture | weeks 31-32 | 37.6 | percentage of participants | |
| the Proportion of Participants With ≥3 Mean Weekly CSBMs Over Weeks 1-2, 11-12, 15-16, 19-20, 31-32. | Prucalopride | weeks 31-32 | 38.5 | percentage of participants | |
| the Proportion of Participants With ≥1 Increase in Mean Weekly CSBMs From Baseline Over Weeks 1-2, 3-8, 11-12, 15-16, 19-20, 31-32. | Electro-acupuncture | weeks 1-2 | 49.5 | percentage of participants | |
| the Proportion of Participants With ≥1 Increase in Mean Weekly CSBMs From Baseline Over Weeks 1-2, 3-8, 11-12, 15-16, 19-20, 31-32. | Prucalopride | weeks 1-2 | 61.5 | percentage of participants | |
| the Proportion of Participants With ≥1 Increase in Mean Weekly CSBMs From Baseline Over Weeks 1-2, 3-8, 11-12, 15-16, 19-20, 31-32. | Electro-acupuncture | weeks 3-8 | 66.4 | percentage of participants | |
| the Proportion of Participants With ≥1 Increase in Mean Weekly CSBMs From Baseline Over Weeks 1-2, 3-8, 11-12, 15-16, 19-20, 31-32. | Prucalopride | weeks 3-8 | 63.3 | percentage of participants | |
| the Proportion of Participants With ≥1 Increase in Mean Weekly CSBMs From Baseline Over Weeks 1-2, 3-8, 11-12, 15-16, 19-20, 31-32. | Electro-acupuncture | weeks 11-12 | 63.5 | percentage of participants | |
| the Proportion of Participants With ≥1 Increase in Mean Weekly CSBMs From Baseline Over Weeks 1-2, 3-8, 11-12, 15-16, 19-20, 31-32. | Prucalopride | weeks 11-12 | 63.7 | percentage of participants | |
| the Proportion of Participants With ≥1 Increase in Mean Weekly CSBMs From Baseline Over Weeks 1-2, 3-8, 11-12, 15-16, 19-20, 31-32. | Electro-acupuncture | weeks 15-16 | 65.7 | percentage of participants | |
| the Proportion of Participants With ≥1 Increase in Mean Weekly CSBMs From Baseline Over Weeks 1-2, 3-8, 11-12, 15-16, 19-20, 31-32. | Prucalopride | weeks 15-16 | 66.2 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02047045/results